Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Judo Bio logo — Creating oligonucleotide medicines delivered to the kidney,...

Judo Bio

Creating oligonucleotide medicines delivered to the kidney, silencing target genes to treat systemic and renal diseases.

Founded 2021 United States Cambridge, United States 32 employees Series A Total: $100.00M Biotechnology, Health and Wellness +1

General Information

Company Name Judo Bio
Founded Year 2021
Location United States Cambridge, United States
Employees 32
Industries Biotechnology, Health and Wellness, Life Sciences
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Judo Bio. To contact Judo Bio, visit judo.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Judo Bio compare?

A PDF of Judo Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Judo Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Judo Bio

Judo Bio is a biotechnology startup founded in 2021, headquartered in the United States. The company's slogan "Creating oligonucleotide medicines delivered to the kidney, silencing target genes to treat systemic and renal diseases," encapsulates its mission. Judo Bio's pioneering approach involves the use of the STRIKE (Selectively Targeting RNA Into KidnEy) platform to develop ligand-RNA conjugate drugs aimed at specific kidney cell types. This method enables gene silencing of disease-modifying target genes, particularly for systemic and renal diseases. Their initial pipeline programs, megalin-STRIKERs, are designed to leverage the megalin receptor family to deliver siRNA therapeutics to the proximal tubule of the kidney, thereby silencing mRNA expression of specific solute carrier proteins (SLCs) and inhibiting the uptake of circulating solutes linked to systemic diseases. Currently, there is no public information available regarding Judo Bio's last investment or its associated investors.

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $75.00M 7
Atlas Venture Alexandria Venture Investments Digitalis Ventures
Atlas Venture, Alexandria Venture Investments +5
01 Oct 2024
Seed $25.00M 1
The Column Group
The Column Group
01 Apr 2024

FAQ About Judo Bio

Creating oligonucleotide medicines delivered to the kidney, silencing target genes to treat systemic and renal diseases.
Judo Bio was founded in 2021.
Judo Bio is headquartered in Cambridge, United States.
Judo Bio operates in Biotechnology, Health and Wellness and Life Sciences.
Judo Bio has approximately 32 employees.
Judo Bio has completed 2 funding rounds, raising a total of $100.00M. The latest funding stage is Series A.

We're actively collecting intelligence on Judo Bio.

Source: BounceWatch company record for Judo Bio, https://bouncewatch.com/company/judo-bio, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout